February 10, 2026
GlaxoSmithKline and Teva told a Delaware federal judge that they've settled GSK's decade-long "skinny label" patent fight over heart failure medication and asked the court to end the case.
March 06, 2025
GlaxoSmithKline has told a Delaware federal judge that Teva's request for a new trial in the drugmakers' decade-long, $235 million "skinny label" patent fight over heart failure medication is an "eighth bite at the same apple."
February 11, 2025
Teva Pharmaceuticals has urged a Delaware federal judge to reject GlaxoSmithKline's request to enhance a $235 million infringement award over a skinny label version of GSK's cardiovascular drug Coreg, saying judges at all levels of courts made clear the case wasn't open and shut.
January 28, 2025
GlaxoSmithKline LLC is urging a Delaware federal judge to enhance the $235 million damages award a jury issued against Teva Pharmaceuticals USA Inc. in 2017, now that the dispute over skinny label infringement has returned to district court.
December 13, 2024
A number of key issues remain live in the $400 million fight between Teva Pharmaceuticals and GlaxoSmithKline over whether the generic-drug maker induced healthcare providers to infringe the brand-name company's heart drug patent, including the availability of a new trial, a Delaware federal judge has said.
July 11, 2024
A GlaxoSmithKline lawyer has urged a Delaware federal judge to make up his mind about a nearly $400 million patent case against Teva Pharmaceuticals in light of unrelated "opioid-related cases" that the Israeli generic-drug maker has been settling in the billions of dollars.
March 28, 2018
A Delaware federal judge on Wednesday released Teva Pharmaceutical Industries Ltd. from a $235 million verdict over its generic version of GlaxoSmithKline LLC's heart medication Coreg, finding Teva did not infringe a patent covering the drug.
October 26, 2017
Attorneys for GlaxoSmithKline and Teva Pharmaceuticals both told a Delaware federal judge on Thursday that far more than money is at stake in post-trial challenges to a $235 million heart drug infringement award won by GSK in June.
August 28, 2017
One month after a Delaware federal jury found Teva Pharmaceuticals willfully infringed a patent tied to the hypertension drug Coreg and handed GlaxoSmithKline a $235 million verdict, Teva on Friday pushed for the court to grant it judgment or a new trial, and GSK asked for enhanced damages and attorney fees.
June 21, 2017
Teva Pharmaceuticals USA Inc. should pay GlaxoSmithKline LLC more than $235 million for willfully infringing a patent tied to the hypertension drug Coreg, a Delaware federal jury said.